Advancements in the Blood–Brain Barrier Penetrating Nanoplatforms for Brain Related Disease Diagnostics and Therapeutic Applications

Thangudu, Suresh; Cheng, Fong‐Yu; Su, Chia‐Hao

doi:10.3390/polym12123055

Cited by 48 publications

(34 citation statements)

References 155 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The Blood-Brain Barrier (BBB) is the natural guard of the brain, which inhibits unwanted molecules to cross the brain tissues [68]. Unfortunately, brain-related or neurological diseases have increased tremendously in the last few decades.…”

Section: Discussionmentioning

confidence: 99%

In silico tool for predicting and designing Blood-Brain Barrier Penetrating Peptides

Kumar¹,

Patiyal²,

Dhall³

et al. 2021

Preprint

View full text Add to dashboard Cite

Blood-brain-barrier is a major obstacle in treating brain-related disorders as it does not allow to deliver drugs in the brain. In order to facilitate delivery of drugs in brain, we developed a method for predicting blood-brain-barrier penetrating peptides. These blood-brain barriers penetrating peptides (B3PPs) can act as therapeutic as well as drug delivery agents. We trained, tested, and evaluated our models on blood-brain-barrier peptides obtained from the B3Pdb database. First, we compute a wide range of peptide features then we select relevant peptide features. Finally, we developed numerous machine learning-based models for predicting blood-brain-barrier peptides using selected features. Our model based on random forest performed best on the top 80 selected features and achieved a maximum 85.08% accuracy with 0.93 AUROC. We also developed a web server, B3pred that implements our best models. It has three major modules that allow users to; i) predict B3PPs, ii) scanning B3PPs in a protein sequence, and iii) designing B3PPs using analogs. Our web server and standalone software is freely available at https://webs.iiitd.edu.in/raghava/b3pred/.

show abstract

Section: Discussionmentioning

confidence: 99%

In silico tool for predicting and designing Blood-Brain Barrier Penetrating Peptides

Kumar¹,

Patiyal²,

Dhall³

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…Nanoparticles can serve as drug delivery carriers to cross the BBB (Thangudu et al, 2020). Nanoparticles have many advantages.…”

Section: The Combined Application Of Antibody Fragments and Nanoparticles In Admentioning

confidence: 99%

“…And they can help drugs to target at tissues specifically and increase efficacy. Therefore, less doses can be effective and adverse effects will be decreased (Thangudu et al, 2020). Nanoparticles can pass through the BBB because their small sizes, often between 1 and 100 nm (Thangudu et al, 2020).…”

Section: The Combined Application Of Antibody Fragments and Nanoparticles In Admentioning

confidence: 99%

“…Therefore, less doses can be effective and adverse effects will be decreased (Thangudu et al, 2020). Nanoparticles can pass through the BBB because their small sizes, often between 1 and 100 nm (Thangudu et al, 2020). Different kinds of nanoparticles have been used in the diagnosis and treatment of AD, including polymeric nanoparticles, liposomes, magnetic nanoparticles and etc (Liu et al, 2019).…”

Section: The Combined Application Of Antibody Fragments and Nanoparticles In Admentioning

confidence: 99%

“…Superparamagnetic iron oxide nanoparticles (SPIONs) are usually used in imaging as MRI contrast agents (Thangudu et al, 2020 made a system called W20/ XD4-SPIONs. They studied the effects of it on diagnosing and treating AD.…”

Section: The Combination Of Antibody Fragments and Superparamagnetic Iron Oxide Nanoparticlesmentioning

confidence: 99%

See 2 more Smart Citations

Application of Antibody Fragments Against Aβ With Emphasis on Combined Application With Nanoparticles in Alzheimer’s Disease

Sun

et al. 2021

Front. Pharmacol.

View full text Add to dashboard Cite

Alzheimer’s disease (AD) is one of the most common neurodegenerative diseases and accumulating evidences suggest a key role of amyloid-β (Aβ) peptide in the pathogenesis of AD. According to the amyloid cascade hypothesis, the imbalance of producing and clearing Aβ is the beginning of neurodegeneration and dementia. Consequently, immunotherapy becomes popular through using antibodies against Aβ. However, many studies of monoclonal antibodies were stopped because adverse effects appeared or there were no evident benefits observed. Some antibody fragments have many advantages over monoclonal antibodies, such as small sizes, lack of the crystallizable fraction (Fc) and so on. There are three main antibody fragments, including single chain variable fragments (scFvs), Fab fragments and single-domain antibody fragments. Nanoparticles can facilitate the entry of drug molecules across the blood-brain barrier, making them become excellent carriers. Various kinds of nanoparticles have been applied in the treatment of AD. The combination of nanoparticles and antibody fragments against amyloid-β can be used in the diagnosis and treatment of Alzheimer’s disease. In this review, we summarize the progress of antibody fragments against amyloid-β in AD, focusing on the combined application with nanoparticles in the diagnosis and treatment of AD.

show abstract

Identification of novel quinazolinone hybrids as cytotoxic agents against C6 glioma cell lines

Shankaraiah

Bhavani

Vodnala

et al. 2022

J Chinese Chemical Soc

View full text Add to dashboard Cite

Novel quinazolinone‐triazole hybrid heterocycles were identified as cytotoxic agents to inhibit glioblastoma cell proliferation. These compounds were synthesized using click reaction by building a triazole linker on quinazolinone and tested for cytotoxicity on C6 glioma cell lines, a facsimile of glioblastoma multiforme. Few of these series significantly reduced the proliferation of cell lines with IC50 8–15 μM and may act as fetching leads for glioblastoma therapies. The binding affinity and ligand‐receptor interaction between hybrids and rat thymidylate synthase were investigated using molecular docking techniques.

show abstract

Advancements in the Blood–Brain Barrier Penetrating Nanoplatforms for Brain Related Disease Diagnostics and Therapeutic Applications

Cited by 48 publications

References 155 publications

In silico tool for predicting and designing Blood-Brain Barrier Penetrating Peptides

In silico tool for predicting and designing Blood-Brain Barrier Penetrating Peptides

Application of Antibody Fragments Against Aβ With Emphasis on Combined Application With Nanoparticles in Alzheimer’s Disease

Identification of novel quinazolinone hybrids as cytotoxic agents against C6 glioma cell lines

Contact Info

Product

Resources

About